87 related articles for article (PubMed ID: 16739316)
1. Palliative chemotherapy with trofosfamide in advanced prostate cancer.
Salminen EK; Sundström J; Nikkanen V
Anticancer Res; 2006; 26(1B):539-42. PubMed ID: 16739316
[TBL] [Abstract][Full Text] [Related]
2. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas.
Hartmann JT; Oechsle K; Mayer F; Kanz L; Bokemeyer C
Anticancer Res; 2003; 23(2C):1899-901. PubMed ID: 12820475
[TBL] [Abstract][Full Text] [Related]
4. Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer.
Pintér O; Molnár J; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Hollman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I; Pajor L
In Vivo; 2005; 19(4):787-92. PubMed ID: 15999550
[TBL] [Abstract][Full Text] [Related]
5. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
8. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
10. Trofosfamide in patients with pancreatic cancer.
Schmidt-Sandte W; Dageförde J; Klapdor R; Wagner T; Wiedemann GJ
Anticancer Res; 1999; 19(4A):2485-7. PubMed ID: 10470179
[TBL] [Abstract][Full Text] [Related]
11. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
15. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
16. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
[TBL] [Abstract][Full Text] [Related]
17. [The place of estramustine in the treatment of prostate cancer].
Pintér O; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Holman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I
Orv Hetil; 2005 Mar; 146(12):553-7. PubMed ID: 15853064
[TBL] [Abstract][Full Text] [Related]
18. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
Swanson GP; Faulkner J; Smalley SR; Noble MJ; Stephens RL; O'Rourke TJ; Weiss GR; Quick DP; Thompson IM; Crawford ED
J Urol; 2006 Aug; 176(2):548-53; discussion 553. PubMed ID: 16813886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
